No Detail Found!

Cascade Screening of Hereditary Angioedema in Pakistan

Author(s)
Muhammad Hussain Department of Immunology, The Armed Forces Institute of Pathology / CMH / NUMS,Rawalpindi,Pakistan
Muhammad Omair Riaz Department of Immunology, The Armed Forces Institute of Pathology / CMH / NUMS,Rawalpindi,Pakistan
Mustajab Alam Department of Immunology, The Armed Forces Institute of Pathology / CMH / NUMS,Rawalpindi,Pakistan
Muhammad Aftab Hassan Department of Immunology, The Armed Forces Institute of Pathology / CMH / NUMS,Rawalpindi,Pakistan
Abstract
To establish cascade family screening of newly diagnosed hereditary angioedema (HAE) patients. Study Design: Cross-sectional, observational study. Place and Duration of the Study:Department of Immunology, The Armed Forces Institute of Pathology / CMH / NUMS, Rawalpindi, Pakistan, from September 2021 to June 2024. Methodology: Eighty-nine parents, siblings, and children of 10 diagnosed patients of HAE were screened. Thirty-two family members were screened by using C1 esterase and complement C4 levels, whereas 57 patients were not available or willing for blood samples, and a questionnaire designed for HAE was recorded from patients / index cases. Baseline characteristics of HAEIndex and HAE-Screened patients were analysed using inferential statistics (independent t-test, Chi-square / Fisher's exact, and Mann-Whitney U test), selected based on data distribution (assessed by the Shapiro-Wilk s test). Results: A total of 10 cases were followed for screening in families. Upon cascade screening of 89 individuals, 16 con rmed and 24 probable cases of HAE among family members (symptomatic and asymptomatic) were identi ed. Out of these 40 positive patients, 26 were male and 14 were female. Three patients among these screened individuals died secondary to laryngeal oedema. Out of ten index cases, two did not have any family history of hereditary angioedema, hence suspected for de novo mutation in the SERPING-1 gene. Conclusion: Cascade screening helps in facilitating early diagnosis of asymptomatic or mildly symptomatic family members of HAE patients. This will provide better guidance for avoiding potential triggers, appropriate prophylaxis, and better management of HAE patients. Young patients of HAE need genetic counselling for a 50% risk of HAE in o spring and are recommended for prenatal diagnosis.
Publication Details
Page(s) 580-584
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 05, Year: 2025

Request the full text from PASTIC

Keywords
Screening, Screening, C1 esterase, C4, Hereditary angioedema, Laryngeal oedema
References
Maurer M,Magerl M,Betschel S,Aberer W,Ansotegui IJ,Aygoren-Pursun E .2022 .The international WAO/EAACI guideline for the management of hereditary angioedema The 2021 revision and update. World Allergy Organ J, 100(3) : 100627.
Guryanova I,Su ritti C,Parolin D,Zanichelli A,Ishchanka N,Polyakova E .2021 .Hereditary angioedema due to C1 inhibitor de ciency in Belarus: Epidemiology, access to diagnosis and seven novel mutations in SERPING1 gene. Clin Mol Allergy, 10(1) : .
Longhurst HJ,Bork K. .2019 .Hereditary angioedema: An update on causes, manifestations and treatment. Br J Hosp Med, 80(7) : 391-8.
Jayasinghe M,Caldera D,Prathiraja O,Jena R,Co ePierre JA,Agyei J .2022 .A comprehensive review of bradykinin-induced angioedema versus histamineinduced angioedema in the emergency department. Cureus, 10(11) : .
Bork K,Hardt J,Witzke G .2012 .Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH de ciency. J Allergy Clin, 05(3) : 692-7.
Zotter Z,Csuka D,Szabo E,Czaller I,Nebenfuhrer Z,Temesszentandrasi G .2014 .et a.l The in uence of trigger factors on hereditary angioedema due to C1-inhibitor de ciency. Orphanet J Rare Dis, 10 : 1750.
Patel G,Pongracic JA .2019 .Hereditary and acquired angioedema. Allergy Asthma Proc, 40(6) : 441-5.
Sobotkova M,Zachova R,Hakl R,Kuklinek P,Kralickova P,Krcmova I .2021 .Acquired angioedema with C1 inhibitor de ciency: Occurrence, clinical features, and management: A nationwide retrospective study in the Czech Republic patients. Int Arch Allergy Immunol, 10(7) : 642-9.
Manning ME .2021 .Recognition and management of hereditary angioedema: Best practices for dermatologists. Dermatol Ther (Heidelb), 10(5) : 021-38.
Fraser FC .1974 .Genetic counseling. Am J Hum Genet, 26(5) : 636-9.
Jindal AK,Reshef A,Longhurst H .2021 .Mitigating disparity in health-care resources between countries for management of hereditary angioedema. Clin Rev Allergy Immunol, 10(3) : 372-85.
Zhang X,Wang X .2022 .Li L. Long-term prophylaxis with androgens in the management of hereditary angioedema. Orphanet J Rare Dis, 10(1) : 95.
Jindal AK,Singh A,Anjani G,Kaur A,Jaiswal M,Chopra S .2020 .Successful perioperative management of three patients with hereditary angioedema without C1 esterase inhibitor therapy: A developing country perspective. Immunobiology, 152022(6) : 152022.
Banerji A,Davis KH,Brown TM,Hollis K,Hunter SM,Long J .2020 .Patient-reported burden of hereditary angioedema: Findings from a patient survey in the United States. , 02(6) : 600-7.
Aabom A,Andersen KE,Perez-Fernandez E,Caballero T,Bygum A .2015 .Health-related quality of life in Danish patients with hereditary angioedema. Acta Derm Venereol, 10(2) : 00015555-1835.
Karim Y,Gri ths H,Deacock S H .2003 .Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol, 010595(2) : 213-4.
Jindal AK,Chiang V,Barman P,Sil A,Chawla S,Au EY .2023 .Screening for type II hereditary angioedema the poor man s c1-inhibitor function. J Allergy Clin Immunol Glob, 100179(1) : 100179.
Minafra FG,Goncalves TR,Alves TM,Pinto JA .2022 .The mortality from hereditary angioedema worldwide: A review of the real-world data literature. Clin Rev Allergy Immunol, 10(1) : 232-9.
Wong JC,Chiang V,Lam K,Tung E,Au EY,Lau CS .2022 .Prospective study on the e cacy and impact of cascade screening and evaluation of hereditary angioedema (CaSE-HAE). J Allergy Clin Immunol Pract, 07(11) : 2896-903.
0

Citations

0

Downloads

34

Views